Edition:
United Kingdom

Eleven Biotherapeutics Inc (EBIO.OQ)

EBIO.OQ on NASDAQ Stock Exchange Global Market

0.86USD
12 Jan 2018
Change (% chg)

-- (--)
Prev Close
$0.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
153,611
52-wk High
$2.53
52-wk Low
$0.63

Chart for

About

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company's product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and... (more)
No analyst recommendations are available for .

Overall

Beta: 3.54
Market Cap(Mil.): $37.55
Shares Outstanding(Mil.): 24.70
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 84.57 16.44
EPS (TTM): -- -- --
ROI: -- 3.42 10.61
ROE: -- 5.38 14.21

BRIEF-Eleven Biotherapeutics reports Q3 loss per share $0.37

* Eleven Biotherapeutics reports third quarter 2017 financial results

20 Nov 2017

BRIEF-Eleven Biotherapeutics files for non timely 10-Q

* Eleven biotherapeutics inc files for non timely 10-Q - Sec Filing‍​ Source text: (http://bit.ly/2zZDGkA) Further company coverage:

15 Nov 2017

BRIEF-Eleven Biotherapeutics CFO steps down; Richard Fitzgerald named interim CFO

* Eleven Biotherapeutics appoints Richard Fitzgerald as interim chief financial officer

13 Oct 2017

BRIEF-Eleven Biotherapeutics ‍appoints Richard Fitzgerald as interim CFO

* Eleven Biotherapeutics Inc - ‍appointed Richard F. Fitzgerald, age 54, as company's interim Chief Financial Officer, effective October 13, 2017​

13 Oct 2017

BRIEF-Eleven Biotherapeutics files for offering of $12.5 mln common stock

* Eleven biotherapeutics inc- files for offering of $12.5 million common stock Source text for Eikon: (http://bit.ly/2y1EGTF) Further company coverage:

04 Oct 2017

BRIEF-Eleven Biotherapeutics Q2 loss per share $0.30

* Eleven Biotherapeutics reports second quarter 2017 financial results

14 Aug 2017

Earnings vs. Estimates